Pharma & Healthcare
M&A, COVID-19 and other social risks to drive credit quality
- Pharmaceuticals: Which segments will take longer to recover patient volumes and will be more prone to M&A?
- Medical Devices: What is the shape of the recovery in medical devices? What are the key downside risks to a sustainable rebound?
- Laboratories: How long will the tailwind from COVID-19 testing last for? What will be the credit impact of M&A resumption?
- Healthcare facilities: What is the outlook beyond government support? Expectations regarding M&A and regulation
An error occurred trying to play the stream. Please reload the page and try again.Close